Sarepta Therapeutics (SRPT) Short-Term Debt repayments (2017 - 2026)
Sarepta Therapeutics' quarterly Short-Term Debt repayments came in at $250.0 million in Q1 2026, up 9900.0% quarter-over-quarter from $2.5 million in Q1 2017.
Sarepta Therapeutics has reported Short-Term Debt repayments for 2 years, with the latest figure at $250.0 million in Q1 2026.
- For the quarter ending Q1 2026, Short-Term Debt repayments changed N/A year-over-year to $250.0 million; the trailing twelve-month figure through Mar 2026 stood at $250.0 million (up 9900.0% YoY), and the FY2018 full-year result was $30.0 million, up 100.0% from the prior year.
- Short-Term Debt repayments for Q1 2026 stood at $250.0 million, up from $2.5 million in the prior quarter.
- The five-year high for Short-Term Debt repayments was $250.0 million in Q1 2026, with the low at $250.0 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 102,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | 250.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 250.00 Mn |
| Mar 31, 2026 | 250.00 Mn |
| Mar 31, 2017 | 2.50 Mn |
| Mar 31, 2017 | 2.50 Mn |